Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Abstract Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor (EGFR) signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: NCT04028778), 315 patients with treatment-naïve, EGFR-m...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hua-Qiang Zhou, Ya-Xiong Zhang, Gang Chen, Qi-Tao Yu, Hua Zhang, Guo-Wu Wu, Di Wu, Ying-Cheng Lin, Jun-Fei Zhu, Jian-Hua Chen, Xiao-Hua Hu, Bin Lan, Ze-Qiang Zhou, Hai-Feng Lin, Zi-Bing Wang, Xiao-Lin Lei, Suo-Ming Pan, Li-Ming Chen, Jian Zhang, Tian-Dong Kong, Ji-Cheng Yao, Xin Zheng, Feng Li, Li Zhang, Wen-Feng Fang
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Publishing Group 2024-08-01
Col·lecció:	Signal Transduction and Targeted Therapy
Accés en línia:	https://doi.org/10.1038/s41392-024-01927-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!